BMY 43351

structure given in first source

Also Known As:

7-(4-(4-cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxyl-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one; BMY-43351; Piperazine, 1-(cyclohexylmethyl)-4-(4-((2,3-dihydro-2-oxo-1H-imidazo(4,5-b)quinolin-7-yl)oxy)-1-oxobutyl)-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - BMY 43351: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - BMY 43351: 1

Related Diseases

1.	Coronary Stenosis (Coronary Artery Stenosis) 07/01/1991 - "Similarly, in the coronary artery stenosis-occlusion model, BMY-43351 demonstrated impressive activity, significantly inhibiting arterial thrombosis at intraduodenal doses as low as 1 micrograms/kg. The potential use of BMY-43351 as adjunct therapy in thrombolysis was suggested in a series of experiments where this drug was used in combination with a thrombolytic regimen of stretokinase plus heparin. "
2.	Thrombosis (Thrombus) 07/01/1991 - "Similarly, in the coronary artery stenosis-occlusion model, BMY-43351 demonstrated impressive activity, significantly inhibiting arterial thrombosis at intraduodenal doses as low as 1 micrograms/kg. The potential use of BMY-43351 as adjunct therapy in thrombolysis was suggested in a series of experiments where this drug was used in combination with a thrombolytic regimen of stretokinase plus heparin. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)

Related Therapies and Procedures

1.	Therapeutics